Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease

Figure 2 Senicapoc is anti-fibrotic in toxin-induced liver disease. A: Eight weeks after administration of TAA, livers exhibited increased hydroxyproline (collagen) content (^aP < 0.05 vs sham). Animals randomized to Senicapoc between weeks 8 and 16, exhibited reduced liver fibrosis at week 16 (^cP < 0.05 vs TAA + vehicle). B: Picosirus red stained livers (20 ×) from representative sham, TAA + vehicle or TAA + Senicapoc-treated animals (16 wk TAA; 8 wk drug) are shown. Intervention with Senicapoc reduced hepatic collagen accumulation (^cP < 0.05 vs TAA + vehicle).